>>> US Notable movers of interest


Notable movers of interest

Large Cap Gainers
  • AZN (67.01 +5.54%): Seeing reports that Pfizer (PFE) is considering a GBP 60 bln (~$100 bln) bid for the company
  • NEM (24.83 +5.48%): Strength on WSJ report that merger talks between NEM and Barrick Gold (ABX) have broken down
  • CHTR (124.22 +5.42%): Reuters reporting that Comcast (CMCSA) is in talks with Charter over divestitures related to Comcast's takeover of Time Warner Cable (TWC)
Large Cap Losers
  • TRP (44.83 -3.74%): Weakness following further delay on decision of Keystone XL pipeline; downgraded to Sector Perform from Sector Outperform at CIBC World Markets
  • ABX (17.35 -3.50%): Weakness on WSJ report that merger talks with Newmont Mining (NEM) have broken down
  • TCK (21.82 -1.13%): Announced it has subscribed for and acquired an additional 2 mln common shares of Erdene Resource Development at a cost of $0.175 per common share, in a private placement conducted by Erdene
Mid Cap Gainers
  • AMD (4.14 +12.33%): Beat quarterly EPS by $0.02 ($0.02 vs $0.00 estimate), revs rose 28.4% yoy to $1.4 bln vs $1.34 bln estimate; sees Q2 revs +0-6% quarter over quarter (~$1.40-1.48 bln) vs $1.36 bln estimate
  • CSGP (172.04 +3.89%): Upgraded to Buy from Neutral at B. Riley & Co
  • CPN (22.2 +3.88%): Agreed to sell six Southeast power plants for $1.57 bln
Mid Cap Losers
  • ATHN (136.45 -6.27%): Missed quarterly EPS by $0.05 ($0.12 ex items vs $0.17 estimate), revs rose 29.8% yoy to $163.03 mln vs $170.45 mln estimate; sees FY14 revs of $725-755 mln vs $751 mln estimate, adjusted EPS of $0.98-1.10 vs $1.09 estimate
  • CPHD (45.05 -6.01%): Beat quarterly EPS by $0.06 (-$0.01 ex items vs -$0.07 estimate), revs rose 16.3% yoy to $106.9 mln vs $104.98 mln estimate; sees FY14 EPS of $0.19-0.24 ex items (lowered from $0.24-0.29) vs $0.26 estimate, revs of $446-461 mln vs $457.71 mln estimate
  • LII (86.51 -3.11%): Beat quarterly EPS by $0.01 ($0.42 ex items vs $0.41 estimate), revs rose 4.0% yoy to $695.4 mln vs $701.4 mln estimate; reaffirmed FY14 EPS guidance of $4.20-4.60 ex items vs $4.57 estimate, revs +3-7%